Mitotic chromosomal instability and cancer: Mouse modelling of the human disease

Nature Reviews Cancer

Volumn 10, Issue 2, 2010, Pages 102-115

  Schvartzman, Juan Manuel ^a   Sotillo, Rocio ^a   Benezra, Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; ARRY 520; AURORA KINASE INHIBITOR; AZD 4877; DOCETAXEL; GSK 923295; ISPINESIB; MK 0731; MLN 8237; NAVELBINE; ON 01910; P 276 00; PACLITAXEL; SB 743921; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANAPHASE; ANEUPLOIDY; ASTROCYTOMA; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL VIABILITY; CHROMATID; CHROMATID ABERRATION; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DNA DAMAGE; EPENDYMOMA; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METAPHASE; MITOSIS; MYCOSIS FUNGOIDES; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; SEMINOMA; SOLID TUMOR; STOMACH CANCER; TESTIS CANCER; THYROID CARCINOMA; UTERINE CERVIX CANCER;

ANEUPLOIDY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; CHROMOSOME BREAKAGE; DISEASE PROGRESSION; HUMANS; MITOSIS; MODELS, GENETIC; NEOPLASMS;

EID: 75149140916     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2781     Document Type: Review

References (200)

1. Boveri, T. Über mehrpolige mitosen als mittel zur analyse des zellkerns. Verh. Phys. Med. Ges. Würzburg 35, 67-90 (1902)
2. Boveri, T. Zur Frage der Entstehung Maligner Tumoren (Gustav Fischer, Jena, Germany, 1914).
3. Ricke, R. M., van Ree, J. H. & van Deursen, J. M. Whole chromosome instability and cancer: a complex relationship. Trends Genet. 24, 457-466 (2008).
4. Artandi, S. E. et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406, 641-645 (2000).
5. Garcia-Higuera, I. et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nature Cell Biol. 10, 802-811 (2008).
6. Sotillo, R. et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9-23 (2007)
7. Cleaver, J. E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nature Rev. Cancer 5, 564-573 (2005).
8. Kunkel, T. A. & Erie, D. A. DNA mismatch repair. Annu. Rev. Biochem. 74, 681-710 (2005).
9. Rustgi, A. K. The genetics of hereditary colon cancer. Genes Dev. 21, 2525-2538 (2007).
10. Verdun, R. E. & Karlseder, J. Replication and protection of telomeres. Nature 447, 924-931 (2007).
11. Lobrich, M. & Jeggo, P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nature Rev. Cancer 7, 861-869 (2007).
12. Musacchio, A. & Salmon, E. D. The spindle-assembly checkpoint in space and time. Nature Rev. Mol. Cell Biol. 8, 379-393 (2007).
13. Nasmyth, K. How do so few control so many? Cell 120, 739-746 (2005).
14. Haering, C. H., Farcas, A. M., Arumugam, P., Metson, J. & Nasmyth, K. The cohesin ring concatenates sister DNA molecules. Nature 454, 297-301 (2008).
15. Rieder, C. L., Cole, R. W., Khodjakov, A. & Sluder, G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. J. Cell Biol. 130, 941-948 (1995).
16. Fang, G., Yu, H. & Kirschner, M. W. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 12, 1871-1883 (1998).
17. Shannon, K. B., Canman, J. C. & Salmon, E. D. Mad2 and BubR1 function in a single checkpoint pathway that responds to a loss of tension. Mol. Biol. Cell 13, 3706-3719 (2002).
18. Sudakin, V., Chan, G. K. & Yen, T. J. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell Biol. 154, 925-936 (2001).
19. Wassmann, K. & Benezra, R. Mad2 transiently associates with an APC/p55Cdc complex during mitosis. Proc. Natl Acad. Sci. USA 95, 11193-11198 (1998).
20. Sudakin, V. et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol. Biol. Cell 6, 185-197 (1995).
21. De Antoni, A. et al. The Mad1/Mad2 complex as a template for Mad2 activation in the spindle assembly checkpoint. Curr. Biol. 15, 214-225 (2005)
22. Varetti, G. & Musacchio, A. The spindle assembly checkpoint. Curr. Biol. 18, R591-R595 (2008).
23. Malureanu, L. A. et al. BubR1 N terminus acts as a soluble inhibitor of cyclin B degradation by APC/C (Cdc20) in interphase. Dev. Cell 16, 118-131 (2009).
24. Braunstein, I., Miniowitz, S., Moshe, Y. & Hershko, A. Inhibitory factors associated with anaphase-promoting complex/cyclosome in mitotic checkpoint. Proc. Natl Acad. Sci. USA 104, 4870-4875 (2007).
25. Herzog, F. et al. Structure of the anaphase-promoting complex/cyclosome interacting with a mitotic checkpoint complex. Science 323, 1477-1481 (2009).
26. Nilsson, J., Yekezare, M., Minshull, J. & Pines, J. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nature Cell Biol. 10, 1411-1420 (2008)
27. Wassmann, K., Liberal, V. & Benezra, R. Mad2 phosphorylation regulates its association with Mad1 and the APC/C. EMBO J. 22, 797-806 (2003).
28. Choi, E. et al. BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J. 28, 2077-2089 (2009).
29. Reddy, S. K., Rape, M., Margansky, W. A. & Kirschner, M. W. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446, 921-925 (2007).
30. Stegmeier, F. et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 446, 876-881 (2007).
31. Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602 (1983).
32. Perucho, M. et al. Human-tumor-derived cell lines contain common and different transforming genes. Cell 27, 467-476 (1981).
33. Chang, E. H., Furth, M. E., Scolnick, E. M. & Lowy, D. R. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297, 479-483 (1982).
34. Goldfarb, M., Shimizu, K., Perucho, M. & Wigler, M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296, 404-409 (1982).
35. Land, H., Parada, L. F. & Weinberg, R. A. Cellular oncogenes and multistep carcinogenesis. Science 222, 771-778 (1983).
36. Shih, C., Padhy, L. C., Murray, M. & Weinberg, R. A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261-264 (1981).
37. Pei, L. & Melmed, S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11, 433-441 (1997).
38. Vader, G. & Lens, S. M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 1786, 60-72 (2008).
39. Katayama, H., Brinkley, W. R. & Sen, S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22, 451-464 (2003).
40. Zhang, D. et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 23, 8720-8730 (2004).
41. Lee, S. H., Sterling, H., Burlingame, A. & McCormick, F. Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev. 22, 2926-2931 (2008).
42. Dawlaty, M. M. et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIα. Cell 133, 103-115 (2008).
43. Bernal, J. A. et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nature Genet. 32, 306-311 (2002).
44. Fang, Y. et al. BubR1 is involved in regulation of DNA damage responses. Oncogene 25, 3598-3605 (2006).
45. Hein, J. et al. Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J. Virol. 83, 117-127 (2009).
46. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genet. 38, 1043-1048 (2006).
47. Kronenwett, U. et al. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res. 64, 904-909 (2004).
48. Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 (2004).
49. Dobles, M., Liberal, V., Scott, M. L., Benezra, R. & Sorger, P. K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 101, 635-645 (2000).
50. Baker, D. J. et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nature Genet. 36, 744-749 (2004).
51. Dai, W. et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res. 64, 440-445 (2004).
52. Babu, J. R. et al. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J. Cell Biol. 160, 341-353 (2003).
53. Kalitsis, P., Earle, E., Fowler, K. J. & Choo, K. H. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev. 14, 2277-2282 (2000).
54. Jeganathan, K., Malureanu, L., Baker, D. J., Abraham, S. C. & van Deursen, J. M. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J. Cell Biol. 179, 255-267 (2007).
55. Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25-36 (2006).
56. Li, M., Fang, X., Wei, Z., York, J. P. & Zhang, P. Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J. Cell Biol. 185, 983-994 (2009).
57. Pérez de Castro, I., de Cárcer, G. & Malumbres, M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28, 899-912 (2007).
58. Perera, D. et al. Bub1 maintains centromeric cohesion by activation of the spindle checkpoint. Dev. Cell 13, 566-579 (2007).
59. Jeong, S. J. et al. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res. 64, 8666-8673 (2004).
60. Sze, K. M., Ching, Y. P., Jin, D. Y. & Ng, I. O. Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. J. Biomed. Sci. 11, 920-927 (2004).
61. Wang, X. et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 62, 1662-1668 (2002).
62. Wang, X. et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 21, 2293-2297 (2000).
63. Ren, B. et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes D e v. 16, 245-256 (2002).
64. Hanks, S. et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nature Genet. 36, 1159 (2004).
65. Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122 (2008).
66. Tighe, A., Johnson, V. L., Albertella, M. & Taylor, S. S. Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep. 2, 609-614 (2001).
67. Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166-180 (2007).
68. Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797-802 (2004).
69. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instability in colorectal cancers. Nature 386, 623-627 (1997).
70. Nicholson, J. M. & Duesberg, P. On the karyotypic origin and evolution of cancer cells. Cancer Genet. Cytogenet. 194, 96-110 (2009).
71. Diaz-Rodriguez, E., Sotillo, R., Schvartzman, J. M. & Benezra, R. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc. Natl Acad. Sci. USA 105, 16719-16724 (2008).
72. Thompson, S. L. & Compton, D. A. Examining the link between chromosomal instability and aneuploidy in human cells. J. Cell Biol. 180, 665-672 (2008).
73. Rieder, C. L. & Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637-651 (2004).
74. Brito, D. A. & Rieder, C. L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16, 1194-1200 (2006).
75. Iovino, F., Lentini, L., Amato, A. & Di Leonardo, A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer 5, 38 (2006).
76. Lentini, L., Iovino, F., Amato, A. & Di Leonardo, A. Centrosome amplification induced by hydroxyurea leads to aneuploidy in pRB deficient human and mouse fibroblasts. Cancer Lett. 238, 153-160 (2006).
77. Lentini, L., Pipitone, L. & Di Leonardo, A. Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia 4, 380-387 (2002).
78. Mayhew, C. N. et al. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133, 976-984 (2007).
79. Zheng, L., Flesken-Nikitin, A., Chen, P. L. & Lee, W. H. Deficiency of retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res. 62, 2498-2502 (2002).
80. Quintyne, N. J., Reing, J. E., Hoffelder, D. R., Gollin, S. M. & Saunders, W. S. Spindle multipolarity is prevented by centrosomal clustering. Science 307, 127-129 (2005).
81. Kwon, M. et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes D e v. 22, 2189-2203 (2008).
82. Silkworth, W. T., Nardi, I. K., Scholl, L. M. & Cimini, D. Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. PLoS ONE 4, e6564 (2009).
83. Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282 (2009).
84. Iwanaga, Y. et al. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res. 67, 160-166 (2007).
85. Ko, M. A. et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nature Genet. 37, 883-888 (2005).
86. Holland, A. J. & Cleveland, D. W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nature Rev. Mol. Cell Biol. 10, 478-487 (2009).
87. Wang, X. et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25, 7148-7158 (2006).
88. Swanton, C. et al. Chromosomal instability determines taxane response. Proc. Natl Acad. Sci. USA 106, 8671-8676 (2009).
89. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
90. Meyer, N. & Penn, L. Z. Reflecting on 25 years with MYC. Nature Rev. Cancer 8, 976-990 (2008).
91. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
92. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992).
93. Williams, B. R. et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322, 703-709 (2008).
94. Gonzalo, S. et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nature Cell Biol. 7, 420-428 (2005).
95. in/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc. Natl Acad. Sci. USA 102, 4365-4370 (2005).
96. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253-265 (2004).
97. Huang, H. C, Shi, J., Orth, J. D. & Mitchison, T. J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16, 347-358 (2009).
98. Weinert, T. A. & Hartwell, L. H. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241, 317-322 (1988).
99. Weinert, T. & Hartwell, L. Control of G2 delay by the rad9 gene of Saccharomyces cerevisiae. J. Cell Sci. 12 (Suppl.), 145-148 (1989).
100. Li, R. & Murray, A. Feedback control of mitosis in budding yeast. Cell 66, 519-531 (1991).
101. Hoyt, M. A., Totis, L. & Roberts, B. T. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 66, 507-517 (1991).
102. Li, Y. & Benezra, R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 274, 246-248 (1996)
103. Kops, G. J., Foltz, D. R. & Cleveland, D. W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl Acad. Sci. USA 101, 8699-8704 (2004).
104. Michel, L. S. et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409, 355-359 (2001).
105. Meraldi, P., Draviam, V. M. & Sorger, P. K. Timing and checkpoints in the regulation of mitotic progression. Dev Cell 7, 45-60 (2004).
106. Zhou, H. et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nature Genet. 20, 189-193 (1998).
107. Sen, S. et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J. Natl Cancer Inst. 94, 1320-1329 (2002).
108. Bischoff, J. R. et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17, 3052-3065 (1998).
109. Miyoshi, Y., Iwao, K., Egawa, C. & Noguchi, S. Association of centrosomal kinase STK 15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 92, 370-373 (2001).
110. Baba, Y. et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11, 418-4125 (2009).
111. Gritsko, T. M. et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin. Cancer Res. 9, 1420-1426 (2003).
112. Ablikim, M. et al. Observation of Y(2175) in J/OTT psi-> etaphif0 (980). Phys. Rev. Lett. 100, 102003 (2008).
113. Sakakura, C. et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J. Cancer 84, 824-831 (2001).
114. Twu, N. F. et al. Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer. Eur J. Obstet. Gynecol. Reprod. Biol. 142, 57-63 (2009).
115. Reiter, R. et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 5136-5141 (2006).
116. Lu, L. Y. et al. Aurora A is essential for early embryonic development and tumor suppression. J. Biol. Chem. 283, 31785-31790 (2008).
117. Cowley, D. O. et al. Aurora-A kinase is essential for bipolar spindle formation and early development. Mol. Cell Biol. 29, 1059-1071 (2009).
118. Araki, K., Nozaki, K., Ueba, T., Tatsuka, M. & Hashimoto, N. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J. Neurooncol. 67, 53-64 (2004).
119. Chieffi, P. et al. Aurora B expression in normal testis and seminomas. J. Endocrinol. 181, 263-270 (2004).
120. Gibson, S. E., Zeng, W. F., Weil, R. J. & Prayson, R. A. Aurora B kinase expression in ependymal neoplasms. Appl. Immunohistochem. Mol. Morphol. 16, 274-278 (2008).
121. Chieffi, P. et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 66, 326-333 (2006).
122. Smith, S. L. et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br. J. Cancer 93, 719-729 (2005).
123. Tanaka, S. et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br. J. Surg. 95, 611-619 (2008).
124. Nguyen, H. G. et al. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 23, 2741-2748 (2009).
125. Gemma, A. et al. Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer 29, 213-218 (2000).
126. Hempen, P. M., Kurpad, H., Calhoun, E. S., Abraham, S. & Kern, S. E. A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T. Hum. Mutat. 21, 445 (2003).
127. Shichiri, M., Yoshinaga, K., Hisatomi, H., Sugihara, K. & Hirata, Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 62, 713-717 (2002).
128. Lin, S. F. et al. Expression of hBUB1 in acute myeloid leukemia. Leuk. Lymphoma 43, 385-391 (2002).
129. Yuan, B. et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin. Cancer Res. 12, 405-410 (2006).
130. Moreno-Bueno, G. et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 63, 5697-5702 (2003).
131. Grabsch, H. et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J. Pathol. 200, 16-22 (2003).
132. Pinto, M. et al. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol. 30, 389-395 (2008).
133. Wada, N. et al. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res. 28, 139-144 (2008).
134. Cahill, D. P. et al. Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300-303 (1998).
135. Schliekelman, M. et al. Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res. 69, 45-54 (2009).
136. Baker, D. J. et al. Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J. Cell Biol. 172, 529-540 (2006).
137. Kalitsis, P. et al. Increased chromosome instability but not cancer predisposition in haploinsufficient Bub3 mice. Genes Chromosomes Cancer 44, 29-36 (2005).
138. Mondal, G. et al. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28, 81-92 (2007).
139. Li, D. et al. Overexpression of oncogenic STK15/BTAK/ Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 9, 991-997 (2003).
140. Kim, J. M. et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin. Cancer Res. 11, 473-482 (2005).
141. Ouellet, V. et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 11 9, 599-607 (2006).
142. Marucci, G. et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 453, 599-609 (2008).
143. Singhal, S. et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol. Ther. 2, 291-298 (2003).
144. Fujita, T., Liu, W., Doihara, H. & Wan, Y. Regulation of Skp2-p27 axis by the Cdh1/anaphase-promoting complex pathway in colorectal tumorigenesis. Am. J. Pathol. 173, 217-228 (2008).
145. Lehman, N. L. et al. Oncogenic regulators and substrates of the anaphase promoting complex/ cyclosome are frequently overexpressed in malignant tumors. Am. J. Pathol. 170, 1793-1805 (2007).
146. Wierinckx, A. et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr. Relat. Cancer 14, 887-900 (2007).
147. Weaver, B. A. & Cleveland, D. W. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res. 67, 10103-10105 (2007).
148. Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25-36 (2007).
149. Wikman, H. et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21, 5804-5813 (2002).
150. Kettunen, E. et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet. Cytogenet. 149, 98-106 (2004).
151. Soria, J. C. et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 60, 4000-4004 (2000).
152. Koon, N. et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53, 235-240 (2004).
153. Takeno, S. et al. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer 94, 2874-2881 (2002). (Pubitemid 34547686)
154. Yoshida, T., Tanaka, S., Mogi, A., Shitara, Y. & Kuwano, H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann. Oncol. 15, 252-256 (2004).
155. Ikuerowo, S. O. et al. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int. J. Cancer 11 9, 867-874 (2006).
156. Agarwal, R. et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin. Cancer Res. 15, 3654-3662 (2009).
157. Aaltonen, K. et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br. J. Cancer 100, 1055-1060 (2009).
158. Brandeis, M. et al. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc. Natl Acad. Sci. USA 95, 4344-4349 (1998).
159. Hayama, S. et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 66, 10339-10348 (2006).
160. Perez de Castro, I., de Carcer, G. & Malumbres, M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28, 899-912 (2007).
161. Nomoto, S. et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 18, 7180-7183 (1999).
162. Tsukasaki, K. et al. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene 20, 3301-3305 (2001).
163. Nishigaki, R. et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5, 3205-3213 (2005).
164. Han, S. et al. Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer 88, 1623-1632 (2000).
165. Nam, C. W. et al. Mitotic checkpoint gene MAD1 in hepatocellular carcinoma is associated with tumor recurrence after surgical resection. J. Surg. Oncol. 97, 567-571 (2008).
166. Chi, Y. H., Ward, J. M., Cheng, L. I., Yasunaga, J. & Jeang, K. T. Spindle assembly checkpoint and p53 deficiencies cooperate for tumorigenesis in mice. Int. J. Cancer 124, 1483-1489 (2009).
167. Hernando, E. et al. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int. J. Cancer 95, 223-227 (2001).
168. Percy, M. J. et al. Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells. Genes Chromosomes Cancer 29, 356-362 (2000).
169. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
170. Chen, X. et al. Gene expression patterns in human liver cancers. Mol. Biol. Cell 13, 1929-1939 (2002).
171. Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784-13789 (2001).
172. Heighway, J. et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21, 7749-7763 (2002).
173. Hisaoka, M., Matsuyama, A. & Hashimoto, H. Aberrant MAD2 expression in soft-tissue sarcoma. Pathol. Int. 58, 329-333 (2008).
174. Wang, L. et al. MAD2 as a key component of mitotic checkpoint: a probable prognostic factor for gastric cancer. Am. J. Clin. Pathol. 131, 793-801 (2009).
175. Rimkus, C. et al. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int. J. Cancer 120, 207-211 (2007).
176. Grutzmann, R. et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6, 611-622 (2004).
177. Saez, C. et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18, 5473-5476 (1999).
178. Honda, S. et al. A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer Res. 23, 3775-3782 (2003).
179. Genkai, N., Homma, J., Sano, M., Tanaka, R. & Yamanaka, R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol. Rep. 15, 1569-1574 (2006).
180. Fujii, T. et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43, 1267-1275 (2006).
181. Su, M. C., Hsu, H. C., Liu, Y. J. & Jeng, Y. M. Overexpression of pituitary tumor-transforming gene-1 in hepatocellular carcinoma. Hepatogastroenterology 53, 262-265 (2006).
182. Zhu, X. et al. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res. 26, 1253-1259 (2006).
183. Puri, R., Tousson, A., Chen, L. & Kakar, S. S. Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett. 163, 131-139 (2001).
184. Heaney, A. P. et al. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355, 716-719 (2000).
185. Liang, H. S. et al. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J. Int. Med. Res. 37, 927-938 (2009).
186. Chiriva-Internati, M. et al. The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J. Transl. Med. 6, 15 (2008).
187. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
188. Yan, S. et al. PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res. 69, 3283-3290 (2009).
189. Wang, Z., Yu, R. & Melmed, S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocrinol. 15, 1870-1879 (2001).
190. +/- pituitary tumorigenesis. Mol. Endocrinol. 19, 2371-2379 (2005).
191. Abbud, R. A. et al. Early multipotential pituitary focal hyperplasia in the α-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol. 19, 1383-1391 (2005).
192. Donangelo, I. et al. Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147, 4781-4791 (2006).
193. Simizu, S. & Osada, H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nature Cell Biol. 2, 852-854 (2000).
194. Tokumitsu, Y. et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 15, 687-692 (1999).
195. Wolf, G. et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543-549 (1997).
196. Macmillan, J. C., Hudson, J. W., Bull., S., Dennis, J. W. & Swallow, C. J. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann. Surg. Oncol. 8, 729-740 (2001).
197. Nappi, T. C. et al. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res. 69, 1916-1923 (2009).
198. Lu, L. Y. et al. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol. Cell Biol. 28, 6870-6876 (2008).
199. Jackson, J. R., Patrick, D. R., Dar, M. M. & Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nature Rev. Cancer 7, 107-117 (2007).
200. Sotillo, R., Schvartzman, J. M., Socci, N. D. & Benezra, R. Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal. Nature (in the press).